Bigfoot Biomedical announces a cutting edge poster presentation and product theater at the 2022 American Diabetes Association 82nd Scientific Sessions

MILPITAS, Calif., June 1, 2022–(BUSINESS WIRE)–Bigfoot Biomedical, a mission-driven company dedicated to supporting better health outcomes for people with insulin-dependent diabetes, today announced a groundbreaking presentation of “The First Real World Experience with Bigfoot Unity: A 3- Month Retrospective Analysis” at the 2022 American Diabetes Association (ADA) 82nd Scientific Sessions. The Company will also host product theater at the event focused on the shift from traditional clinical care to remote physiologic monitoring and management of people who care multiple receive daily insulin injections (MDI) The ADA Scientific Sessions will be held virtually and June 3-7 in New Orleans, Louisiana.

“We are excited to deliver major diabetes innovations and present our first real-world data during ADA,” said Jeffrey Brewer, CEO of Bigfoot Biomedical. “Supporting populations using MDI therapy, particularly those with type 2 diabetes, is central to our mission as they have historically had fewer solutions to manage their intensive insulin therapy.

Bigfoot will disclose additional information about the presentation consistent with the American Diabetes Association’s abstract embargo guidelines.

Late Breaking Poster Presentation:
(68-LB) “The First Real World Experience with Bigfoot Unity: A 3 Month Retrospective Analysis”

Presented by Bantwal S. Baliga, MD, Endocrinologist, East Alabama Endocrinology, PC, on Sunday, June 5, 2022 from 12:00 p.m. to 1:00 p.m. CT

Product Theater:
Bigfoot in the Wild—A Real World Experience”

Hear from Bantwal S. Baliga, MD; Vivian Fonseca, MD, Professor of Medicine and Pharmacology, Tulane University; and James Malone, MD, Chief Medical Officer, Bigfoot Biomedical on Monday, June 6, 2022 from 10:15 a.m. to 11:00 a.m. CT

See also  aactWorldFest returns to the Venice Theater this month

About Bigfoot Unity® diabetes management system

Bigfoot unit® The Diabetes Management System received FDA 510(k) clearance in May 2021 for use by persons 12 years and older. The system has connected smart pen caps that recommend insulin doses for people using Multiple Daily Injection (MDI) therapy. The system is the first and only solution for people with type 1 or type 2 diabetes on MDI therapy that directly uses integrated continuous glucose monitoring (iCGM) data from Abbott’s FreeStyle Libre 2 system to provide a To give insulin dose recommendation based on a doctor’s instructions. The dose is displayed directly on a proprietary, connected smart cap for the person’s disposable insulin pens without the need to manually enter glucose data on a separate device.

About Bigfoot Biomedical, Inc.

Bigfoot Biomedical was founded by a team of people with personal connections to both type 1 and type 2 diabetes. We want to change the paradigm of treating diabetes. Bigfoot is an unconventional company that takes an unconventional approach. Unlike others, we look at insulin therapy holistically and use services, support and new business models. We partner with healthcare professionals to bring simple, connected, and comprehensive solutions to the vast number of people overlooked by diabetes innovations. Learn more at www.bigfootbiomedical.com. Follow us @BigfootBiomed on LinkedIn, Twitter, Instagram and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005480/en/

contacts

Jessica Steging
T +1 260 336 6202
[email protected]

Leave a Comment